Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Gritstone bio, Inc. (Nasdaq: GRTS) announced the grant of nonqualified stock options totaling 33,000 shares to three new employees, with an exercise price of $2.71, matching its closing stock price on February 17, 2023. This grant is part of an inducement for the new hires, in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years, starting with 25% on the first anniversary of hire, then monthly thereafter, contingent on continued employment. Gritstone bio aims to develop potent vaccines targeting viral diseases and solid tumors.
Positive
- Granting of stock options may attract skilled talent to the company.
- Stock options tied to the company's stock performance can align employee interests with shareholder value.
Negative
- No immediate financial metrics or performance results presented to suggest significant impact.
Details
News Market Reaction – GRTS
The recorded move for GRTS in the trading session of this news was +0.82%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the Compensation Committee of the company’s Board of Directors granted three employees nonqualified stock options to purchase an aggregate of 33,000 shares of its common stock with an exercise price of
The stock options will vest over a four-year period, with
About Gritstone bio
Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines. We leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets. Independently and with our collaborators, we are advancing a portfolio of product candidates to treat and prevent viral diseases and solid tumors in pursuit of improving patient outcomes and eliminating disease. www.gritstonebio.com
Gritstone Contacts
Investors:
George E. MacDougall
Director, Investor Relations & Corp Comms
Gritstone bio, Inc.
ir@gritstone.com
Media:
Dan Budwick
1AB
(973) 271-6085
dan@1abmedia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.